Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling.
Molecularly targeted drugs inhibit aberrant signaling within oncogenic pathways. Identifying the predominant pathways at work within a tumor is a key step towards tailoring therapies to the patient. Clinical samples pose significant challenges for proteomic profiling, an attractive approach for identifying predominant pathways. The objective of this study was to determine if information obtained from a limited sample (i.e., a single gel replicate) can provide insight into the predominant pathways in two well-characterized breast cancer models.
Version: za2963e q8zaf q8zba q8zcf q8zd4 q8ze1 q8zfe q8zgb